TheStreet contributor David Sobek offers seven forecasts for biotech stocks in 2014.
Biotech investing rarely follows a predictable script, so here's four stocks which may surprise even the most experienced investors in 2014.
New rigosertib data to be presented next month should make investors feel more confident that Onconova has an active blood-cancer drug.
New Revlimid data to be presented next month should convince European regulators to finally approve an important expansion into front-line multiple myeloma therapy.
Vintafolide benefits ovarian cancer patients with no current treatment options, phase II data shows.
Cubist, Cempra and Tetraphase are all developing antibiotics to combat a new wave of scary bacterial superbugs.
David Sobek explains what went wrong with the bull thesis on Ariad Pharma and its leukemia drug Iclusig.
Biotech M&A deals that haven't happened because of price argue against the risk of a bubble.
The rigosertib phase III study will read out in the fourth quarter or first quarter 2014.
Iclusig is not any more toxic than its competing leukemia drugs and the sales potential remains strong.